(Q35776186)

English

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).

scientific article published on 29 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240). (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

phase III clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

cervix uterine cancer

1 reference

based on heuristic

inferred from title

Helen E. B. Michael

13

object named as

Helen Michael

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Bradley J. Monk

4

object named as

Bradley J Monk

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

author name string

Richard T Penson

1

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Helen Q Huang

2

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Lari B Wenzel

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sharon Stockman

5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Harry J Long

6

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Lois M Ramondetta

7

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Lisa M Landrum

8

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Ana Oaknin

9

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Thomas J A Reid

10

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Mario M Leitao

11

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Michael Method

12

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Krishnansu S Tewari

14

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

publication date

29 January 2015

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

301-311

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Improved survival with bevacizumab in advanced cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Anti-angiogenesis agents in metastatic or recurrent cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

The prognostic significance of patient-reported outcomes in cancer clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Vascular endothelial growth factor (VEGF) inhibition--a critical review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

The Functional Assessment of Cancer Therapy scale: development and validation of the general measure

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Pain mechanisms: a new theory

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Attitudes to chemotherapy: comparing views of patients with cancer with those of doctors, nurses, and general public

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

27 July 2018

Factors associated with poor quality of life among cervical cancer survivors: implications for clinical care and clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Therapeutic potential of VEGF and VEGF-derived peptide in peripheral neuropathies.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Validation and reduction of FACT/GOG-Ntx subscale for platinum/paclitaxel-induced neurologic symptoms: a gynecologic oncology group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Quality of life (QOL) outcomes from a randomized trial of cisplatin versus cisplatin plus paclitaxel in advanced cervical cancer: a Gynecologic Oncology Group study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Clinical results and quality of life analysis for the MVAC combination (methotrexate, vinblastine, doxorubicin, and cisplatin) in carcinoma of the uterine cervix: A Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: a Gynecologic Oncology Group Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Repeated measures with zeros.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Small sample inference for fixed effects from restricted maximum likelihood.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4479218

25 September 2018

Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970004-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970004-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Is a patient's self-reported health-related quality of life a prognostic factor for survival in non-small-cell lung cancer patients? A multivariate analysis of prognostic factors of EORTC study 08975

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970004-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(15)70004-5

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q35776186&oldid=2043546987"